Evogene Ltd. (NASDAQ:EVGN) Short Interest Update

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 13,100 shares, an increase of 67.9% from the January 15th total of 7,800 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 66,100 shares, the days-to-cover ratio is currently 0.2 days.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Jane Street Group LLC bought a new stake in Evogene Ltd. (NASDAQ:EVGN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned 0.40% of Evogene as of its most recent SEC filing. 10.40% of the stock is currently owned by institutional investors and hedge funds.

Evogene Stock Performance

Shares of NASDAQ:EVGN traded up $0.07 during mid-day trading on Friday, reaching $1.55. 10,024 shares of the company’s stock were exchanged, compared to its average volume of 27,162. The firm has a market capitalization of $8.31 million, a price-to-earnings ratio of -0.35 and a beta of 1.29. The business’s fifty day moving average price is $1.57 and its 200-day moving average price is $2.37. Evogene has a twelve month low of $1.20 and a twelve month high of $10.40.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings results on Thursday, November 21st. The biotechnology company reported ($1.31) EPS for the quarter. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Evogene in a research note on Friday. They set a “sell” rating on the stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.